1 Non-invasive fasciculation assessment of

2 gastrocnemius failed to show diagnostic or

prognostic utility in ALS

4

5 Authors

- 6 Robbie Muir¹*, Brendan O'Shea¹*, Raquel Iniesta², Urooba Masood¹, Cristina Cabassi¹,
- 7 Domen Planinc¹, Emma Hodson-Tole³, Emmanuel Drakakis⁴, Martyn Boutelle⁴, Christopher
- 8 E Shaw^{1,5,6} & James Bashford¹
- 9 **First authorship is shared.*
- 10

11 Affiliations

- ¹Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience
- 13 Institute, King's College London, London, UK
- ²Department of Biostatistics and Health Informatics, King's College London, London, UK
- ³Department of Life Sciences, Musculoskeletal Sciences and Sports Medicine Research
- 16 Centre, Manchester Metropolitan University, Manchester, UK
- ⁴Department of Bioengineering, Imperial College London, London, UK
- ⁵UK Dementia Research Institute Centre at King's College London, School of Neuroscience,
- 19 King's College London, Strand, London, WC2R 2LS, UK
- ⁶Centre for Brain Research, University of Auckland, 85 Park Road, Grafton, Auckland, 1023,
- 21 New Zealand
- 22
- 23 Correspondence: Dr James Bashford, Maurice Wohl Clinical Neuroscience Institute, King's
- 24 College London, 5 Cutcombe Road, London, SE5 9RT, UK.
- 25 E-mail: james.bashford@kcl.ac.uk
- 26 Website: https://kcl.ac.uk/spiqe
- 27 Twitter: <u>@SPiQEneurology</u>
- 28

29 Word count: 3523 (excluding references and figure legends)

- 30
- 31
- 32

33	Highlights
34	
35	• Fasciculation parameters from the medial gastrocnemius muscle have poor ability to differentiate ALS
36	patients from controls.
37	• Fasciculation parameters from the medial gastrocnemius muscle cannot reliably predict the prognosis
38	of ALS patients.
39	• Future studies should measure more clinically relevant muscles at an earlier stage in the disease course
40	over a protracted period.
41	
42	Abstract
43	
44	Objectives
45	
46	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder, affecting both upper and lower motor
47	neurons. High-density surface electromyography is a non-invasive measure of muscle fasciculations, a
48	phenomenon prevalent early in the disease. Previous studies highlighted the clinical importance of these
49	measures from the biceps brachii muscle. Our study aimed to investigate the diagnostic and prognostic value of
50	the medial gastrocnemius muscle.
51	
52	Methods
53	
54	We performed a retrospective study of 49 ALS and 25 control participants. Means comparisons, logistic
55	regression, receiver operating characteristic analysis, Kaplan-Meier analysis, and a multilevel Cox model were
56	used to determine the predictive utility of fasciculation potential (FP) parameters including FP frequency,
57	median amplitude, and amplitude dispersion.
58	
59	Results
60	
61	FP parameters demonstrated a poor ability to differentiate between ALS and controls, with ROC analysis
62	producing areas under the curve between 0.58 and 0.63. Furthermore, there was no association between FP
63	parameters and ALS prognosis in the Cox model.
64	
65	Conclusions
66	
67	FP parameters from the medial gastrocnemius muscle are not useful for the diagnosis or prognosis of ALS
00 60	patients.
70	
70	
/ 1	

72	Significance
12	Significance

, -	Significance
73	
74	Our results highlight the poor clinical utility of fasciculation quantification in the medial gastrocnemius muscle.
75	Future studies should focus on recordings from more clinically relevant muscles earlier in the disease.
76	
77	Keywords
78	
79	Amyotrophic lateral sclerosis; medial gastrocnemius muscle; high-density surface electromyography;
80	fasciculation potential; biceps brachii muscle; diagnosis; prognosis.
81	
82	
83	List of abbreviations
84	
85	ALS, amyotrophic lateral sclerosis; UMN, upper motor neuron; LMN, lower motor neuron; HDSEMG, high-
86	density surface electromyography; MU, motor unit; FP, fasciculation potential; EMG, electromyography; BB,
87	biceps brachii; ROC, receiver operating characteristic; CHAID, chi squared automatic interaction detection; CI,
88	confidence interval; MG, medial gastrocnemius; ENCALS, European Network to Cure ALS; BFS, benign
89	fasciculation syndrome; PN, peripheral neuropathy; MMN, multifocal motor neuropathy; ALSFRS-R, revised
90	amyotrophic lateral sclerosis functional rating scale; SPiQE, surface potential quantification engine, IQR,
91	interquartile range; ANOVA, analysis of variance.
92	
93	1. Introduction
94	
95	Amyotrophic lateral sclerosis (ALS) is a chronic progressive paralytic disorder, characterised by the
96	degeneration of both upper motor neurons (UMNs) and lower motor neurons (LMNs) (Brown and Al-Chalabi,
97	2017). The ultimate consequence of the condition is progressive muscle weakness leading to death, usually from
98	respiratory failure, with a median survival time of approximately 19 months from diagnosis and 30 months from
99	symptom onset (Gordon, 2013). However, due to disease heterogeneity and several clinical subtypes, it is
100	difficult to predict individual patient survival early in the disease (Van Es et al., 2017).
101	
102	It is estimated that there are 5000 people living with ALS in the UK at any one time (Opie-Martin et al., 2021),
103	its prevalence higher in men than in women and its incidence increasing with age (Gordon, 2013). However, the
104	onset of ALS is often non-specific and mimics several more common, benign conditions (Van Es et al., 2017).
105	To make a diagnosis, clinicians rely on guidelines such as the Gold Coast criteria (Hannaford et al., 2021), taking a median of 11.5 months after symptom enset (Basenoni et al., 2014) to reach a diagnosis, a third of
107	patients' life expectancy (Van Es et al. 2017). As a result in recent years there has been much interest garnered
102	towards identifying the pre-symptomatic stage of the disease and stratifying patients with similar life
109	expectancies. The benefit of such developments would be two-fold. Firstly, by grouping patients into similar
110	clinical subtypes it could allow for the earlier identification of AIS patients. In turn, this would enhance their

111 recruitment into clinical trials when more motor neurons remain viable (De Carvalho et al., 2008), and

112 therapeutic intervention may be more likely to prevent or delay disease progression (Benatar et al., 2019).

113 Secondly, the prognosis of ALS varies greatly and through the development of a reliable prognostic model,

114 patients could take greater control of their lives and make better plans for their future.

115

116 There are several avenues for research, including genetic markers, fluid biomarkers, and neurophysiological 117 techniques (Van Es et al., 2017). In particular, high-density surface electromyography (HDSEMG) provides a 118 promising option as a non-invasive method of recording fasciculations, capable of revealing LMN involvement 119 in body regions otherwise regarded as unaffected (De Carvalho et al., 2008). Fasciculations are spontaneous, 120 involuntary muscle twitches produced by active motor units (MUs), detected as fasciculation potentials (FPs) on 121 electromyography (EMG) (Drost et al., 2007). They are widespread in ALS and can occur in multiple different 122 muscles (Liu et al., 2021) but can also occur in ALS-mimicking disorders and healthy individuals, making their 123 diagnostic utility uncertain (Noto et al., 2018). FPs are frequently the first abnormality recorded by EMG during 124 neurogenic change in ALS (de Carvalho and Swash, 2013), and their importance in its diagnosis has been 125 increasingly recognised, forming a key component of the Gold Coast criteria (Hannaford et al., 2021). While 126 present in healthy individuals and ALS-mimicking disorders, they are shown to have an increased prevalence 127 and specific morphology in ALS (Bashford et al., 2020c). This may be explained by the underlying 128 pathophysiology of the disease, where denervated muscle fibres are reinnervated by surrounding, healthy MUs 129 through the process of chronic partial reinnervation, allowing strength to be maintained early in the disease 130 course (Bashford et al., 2020c). 131

132 A previous HDSEMG study by our group showed that FP frequency from biceps brachii (BB) is a valuable 133 predictive marker of ALS, demonstrating an area under a receiver operating characteristic (ROC) analysis curve 134 of 0.89 (95% confidence interval (CI) 0.81-0.98). Chi squared automatic interaction detection (CHAID) 135 decision tree analysis also confirmed FP frequency to be the single best diagnostic measure, showing an 85.9% 136 predictive accuracy (95% CI 75-93.4%) (Tamborska et al., 2020). Prognostically, previous research has shown 137 that FP frequency increases predominately in the early stage of the disease course (Bashford et al., 2020c, 138 Tsugawa et al., 2018), and the rate of change of this process is associated with a higher disease burden (Wannop 139 et al., 2021, Avidan et al., 2021). However, studies have shown that the frequency and amplitude of FPs may 140 fluctuate as the disease progresses (Bashford et al., 2020c), raising the question to its utility as a diagnostic and 141 prognostic tool. 142

143 Given the evidence provided by our group for the diagnostic and prognostic utility of FP parameters recorded by 144 HDSEMG in the BB muscle (Tamborska et al., 2020, Wannop et al., 2021), the aim of this study was to explore 145 whether these same parameters were equally insightful in the medial gastrocnemius (MG) muscle among 49 146

147

ALS patients and 25 control participants.

- 148
- 149

2. Methods

TO T	
152	
153	2.1 Study design
154	
155	This study is a retrospective data analysis, using data from three observational studies undertaken at King's
156	College Hospital, London, UK. Using the clinical parameters of the patients with ALS, a prospective dataset
157	containing predicted survival length was obtained using the European Network to Cure ALS (ENCALS)
158	Survival Model (Westeneng et al., 2018).
159	
160	2.2 Ethical approval
161	
162	Ethical approval was obtained from Research Ethics Services in the North of Scotland (ref: 15/NS/0103), East
163	Midlands (ref: 17/EM/0221), and Yorkshire and the Humber (ref: 19/YH/0164).
164	
165	2.3 Participants
166	
167	Patients attending the motor nerve clinic at KCH between January 2016 and January 2022 were invited to take
168	part in the studies. These included males and females aged 18-80 who were ambulatory and able to give
169	informed consent. Patients were recruited into two groups: ALS (n=49), and neurological controls (n=8) (Table
170	1). Those recruited into the ALS group were deemed eligible if they were diagnosed with possible, probable, or
171	definite ALS according to the El Escorial criteria within 24 months of symptom onset. Criteria for exclusion
172	included those with atypical or regionally restricted ALS and those with advanced ALS (wheelchair-bound or
173	dependent on non-invasive ventilation). Patients with bulbar onset ALS were required to demonstrate objective
174	involvement in at least one limb.
175	
176	Those recruited into the neurological control group were deemed eligible if they were diagnosed with an ALS-
177	mimicking disorder by a clinician with an expertise in motor neuron disease. The main criterion for exclusion
178	was diagnostic uncertainty. This group consisted of patients with benign fasciculation syndrome (BFS),
179	peripheral neuropathy (PN), and multifocal motor neuropathy (MMN). Electronic health records of these
180	individuals were inspected at a minimum of two years from recruitment, and none had subsequently developed
181	ALS.
182	
183	The healthy control group (n=17) was recruited from Manchester Metropolitan University between May and
184	September 2019 via poster adverts. This group consisted of males and females aged 18-80 who were deemed
185	eligible if they were ambulatory, able to give informed consent, and had no self-reported history of any
186	neurological condition.
187	
188	
189	
190	

191 2.4 Clinical assessment 192 193 All patients' demographic information, including site and date of first symptoms, were recorded where possible. 194 All participants within the ALS and neurological control groups underwent baseline neurological examination, 195 and ALS patients were subsequently classified into the following phenotypes: i) bulbar-onset, ii) cervical-onset, 196 iii) flail arm, iv) lumbar-onset. The disease severity of all participants was determined using the revised 197 amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) at the time of assessment. 198 199 2.5 HDSEMG recording 200 201 Participants underwent either 15- or 30-minute HDSEMG recordings of the BB and MG muscles unilaterally or 202 bilaterally, depending on the original study protocol. The adhesive HDSEMG sensor (comprised of 64 203 electrodes, arranged in an 8 x 8 grid, electrode diameter 4.5mm, inter-electrode distance 8.5mm; TMS 204 International BV, The Netherlands) was applied centrally over the muscle while the patient was asked to relax in 205 a semi-recumbent position. A reference electrode (3 x 5 cm) was located over the olecranon (when recording 206 BB) and over the dorsum of the foot (when recording MG). Signal amplification was carried out using the Refa-207 64 Recording System (TMS International, BV, Netherlands), and the raw HDSEMG data were stored as a 208 Polybench file at 2048Hz/channel and processed using the novel surface potential quantification engine (SPiQE) 209 tool (Bashford et al., 2019). 210 211 2.6 Fasciculation potential parameters 212 213 Of all the summary parameters derived from the HDSEMG data by SPiQE, we focused on the following three 214 for the purpose of this study: FP frequency, FP median amplitude, and FP amplitude dispersion. FP frequency is 215 defined as the number of FPs divided by minutes of analysed recording (FP/min). FP median amplitude is 216 defined as the median peak-peak voltage of all FPs detected in each recording (μ V). Finally, FP amplitude 217 dispersion is defined as the interquartile range (IQR) of all FP amplitudes detected in each recording (μ V). 218 219 2.7 Statistical analysis 220 221 Participant characteristics were summarised using descriptive statistics for all groups. Where bilateral 222 recordings were taken, the values from the side on which the maximal values were recorded were included in 223 the analysis. 224 225 **2.7.1 Diagnostic** 226 227 All values were transformed to log(10) to satisfy normality for the statistical tests and the normal distribution, 228 and homogeneity of variance of the transformed values were investigated using Shapiro-Wilk normality tests, 229 inspection of Q-Q plots, and Levene's tests. Mean comparisons of the FP parameters between groups was 230 carried out using Welch's one-way analysis of variance (ANOVA) with the Games-Howell post hoc test. To

231	assess the association of FP parameters with the diagnosis of ALS, we dichotomised the outcome by combining
232	the neurological and healthy control groups (1= ALS, 0 = not ALS), and performed univariate binary logistic
233	regression, followed by ROC analysis for the assessment of diagnostic utility. To further explore the diagnostic
234	utility, we carried out a CHAID decision tree classification model with 3-fold internal cross-validation, using
235	each of the FP parameters as independent variables. Unless stated otherwise, values were rounded to the nearest
236	third decimal for p-values and the nearest second decimal for remaining values. The threshold for statistical
237	significance was set to $p < 0.05$ and all statistical analyses were carried out using IBM SPSS Statistics software
238	(version 28, IBM Corp, Armonk, NY, USA).
239	2.7.2 Prognostic
240	
241	Prognostic analysis was performed using R version 4.1.1 (R Foundation for Statistical Computing, Vienna,
242	Austria). There were two datasets used in our analysis.
243	
244	Our first analysis used a prospective survival prediction from a cohort of patients using the ENCALS Survival
245	Model. This prediction was based on each patient's disease characteristics at their first assessment. Using the
246	same patient cohort in our second analysis, we followed all patients over time and in those patients who died,
247	we recorded the observed survival time for each patient. Those who were still alive at the recording cut-off
248	point, 22 nd February 2022, were included as censored in our survival analysis.
249	
250	A Kaplan-Meier analysis was used to identify the most statistically significant parameters, which were then
251	included in a Cox proportional hazards model. A multilevel Cox model was chosen to evaluate the relationship
252	between muscle FP parameters and disease prognosis, while accounting for the presence of bilateral muscle
253	recordings. This was performed for both predicted and observed survival times. Both Cox models were then

- evaluated using the cox.zph() function, which showed no violations of the proportional hazards assumption.
- 255

256 <u>3. Results</u>

257

258 3.1 Participant characteristics

259

Characteristics	ALS	Neurological controls	Healthy controls
n =	49	8	17
Sex			
Female (%)	11 (22)	1 (12.5)	7 (41)
Male (%)	38 (78)	7 (87.5)	10 (59)
Age at onset (years)			
Median (IQR)	59 (51-64)		
Bulbar onset			
Bulbar (%)	12 (24.5)		
Non-bulbar (%)	37 (75.5)		

Diagnostic delay

(months)				
Median (IQR)	14 (7-21)			
El Escorial diagnosis		Diagnosis		
Definite (%)	12 (25)	BFS (%)	6 (75)	
Probable (%)	35 (71)	MMN (%)	1 (12.5)	
Possible (%)	2 (4)	PN (%)	1(12.5)	
	2(1)	111(//0)	1 (12.5)	
ALS phenotype				
Bulbar (%)	12 (24 5)			
Cervical (%)	$\frac{12}{21}(42.9)$			
Elail arm (%)	21(+2.7)			
I umbar (%)	$\frac{2}{14}$ (28.6)			
Lumbar (70)	14 (20.0)			
C9orf72 repeat				
expansion				
Positive (%)	2 (4)			
Negative (%)	17 (35)			
Not requested (%)	30 (61)			
That requested (70)	50 (01)			
Age at HDSEMG (years)				
Median (IOR)	61 (53-66)		40 (37-56)	42 (34-62)
Median (IQIC)	01 (55-00)		+0 (37-30)	42 (34-02)
Time from symptom				
onset to HDSEMG				
(months)				
Median (IOR)	24 (18-36)		20 (8-34)	
Median (IQIC)	21(10:50)		20 (0 5 1)	
ALSERS-R score				
Median (IOR)	41 (35-44)			
	11 (55 11)			
Time from symptom				
onset to AI SFRS-R				
(months)				
Median (IOR)	23 (13-38)			
Median (IQIC)	25 (15 50)			
ALSERS-R progression				
rate				
Median (IOR)	0 3 (0 16-0 69)			
	0.5 (0.10 0.07)			
Predicted FVC (%)				
Median (IOR)	95 (76-100)			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
ENCALS risk group				
Verv long (%)	16 (33)			
Long (%)	12 (25)			
Intermediate (%)	11 (22)			
Short (%)	9 (18)			
Very short (%)	1 (2)			
Predicted survival				
(months)				
Median (IOR)	44 (31-63)			
	. (50)			
Observed survival				
(months)				
Median (IOR)	52 (32-73)*			
	(- · - /			

- 261 Table 1: Participant characteristics. Values rounded to the nearest integer where appropriate. *Observed survival data was
- 262 recorded for 21 patients, with 28 surviving patients censored from the analysis. Abbreviations: ALS, amyotrophic lateral
- 263 sclerosis; IQR, interquartile range; BFS, benign fasciculation syndrome; MMN, multifocal motor neuropathy; PN,
- 264 peripheral neuropathy; HDSEMG, high-density surface electromyography; ALSFRS-R, amyotrophic lateral sclerosis
- 265 functional rating scale revised; FVC, forced vital capacity; ENCALS, The European Network to Cure ALS.

266

- 267
- 268
- 269 3.2 Diagnostic
- 270

271 3.2.1 Comparison of fasciculation potential parameters from medial gastrocnemius between groups

272

Fasciculation parameter n =	ALS 49	Neurological controls 8	Healthy controls 17	Statistical significance
FP frequency (FP/min) Median (IQR)	31 (8.25- 92.35)	13.08 (6.54- 35.41)	14.65 (8.55- 33.8)	Welch's ANOVA $W_{2, 19.21} = 1.71$ p = 0.207
FP median amplitude (μV) Median (IQR)	23.6 (20.2- 41.85)*	26.6 (21-39.83)	28.8 (24.95- 34.95)	Welch's ANOVA $W_{2, 19.08} = 0.28$ p = 0.757
FP amplitude dispersion (μV) Median (IQR)	21 (11.08- 31.43) [†]	24.95 (20.5- 31.3)	33.5 (22.3- 56.5)	Welch's ANOVA $W_{2, 23.82} = 2.00$ p = 0.157

274	Table 2: Comparison of fasciculation parameters from medial gastrocnemius between groups. *FP median amplitude data
275	missing from 1 participant (n=48). [†] FP amplitude dispersion data missing from 1 participant (n=48). Abbreviations: ALS,
276	amyotrophic lateral sclerosis; FP, fasciculation potential; min, minute; IQR, interquartile range; ANOVA, analysis of
277	variance.
278	
279	Welch's ANOVA with Games-Howell post-hoc test revealed no statistically significant differences between the
280	groups for each of the FP parameters. The results of these analyses are summarised in Fig. 1 and Table 2.
281	
282	3.2.2 Association of fasciculation potential parameters with the diagnosis of ALS
283	
284	In the univariate binary logistic regression, none of the FP parameters were significantly associated with the
285	diagnosis of ALS (FP frequency, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.117$; FP median amplitude, $p = 0.910$; FP amplitude dispersion, $p = 0.910$; FP amplitude dispersion, $p = 0.910$; FP median amplitude dispersion, $p = 0.910$;
286	0.083).
287	
288	

289	3.2.3 Assessment of diagnostic utility
290	
291	We further explored the diagnostic utility of these FP parameters by carrying out a ROC analysis (Fig. 2). FP
292	frequency, FP median amplitude and FP amplitude dispersion displayed areas under the curve (AUCs) of 0.61
293	(95% CI 0.48-0.74, p = 0.134), 0.58 (95% CI 0.44-0.71, p = 0.299), and 0.63 (95% CI 0.50-0.76, p = 0.073)
294	respectively, each indicative of poor diagnostic instruments. Lastly, we carried out a CHAID decision tree
295	classification model of ALS, using the FP parameters from the MG alone as independent variables. Due to their
296	redundancy, none of the MG FP parameters were included as independent variables in the model.
297	
298	
299	3.3 Prognostic
300	
301	3.3.1 Association of fasciculation potential parameters with the prognosis of ALS
302	
303	Median values (with IQR) across the cohort for FP frequency, FP median amplitude, and FP amplitude
304	dispersion were 38.5 FP/min (10.3-77.6), 24.9 μ V (21.3-45.2), and 24.3 μ V (14.8-37.9), respectively. Log-rank
305	analysis of the Kaplan-Meier curves for our predicted survival showed no statistically significant differences for
306	any of the muscle FP parameters, as seen in Fig. 3. However, there was a clear divergence between the
307	dichotomized values of FP median amplitude, therefore this parameter was chosen for Cox proportional hazards
308	analysis. FP median amplitude was associated with a hazard ratio of $1.003 (0.97 - 1.03, p = 0.83)$ after
309	accounting for bilateral recordings in our dataset.
310	
311	Similarly, as seen in Fig. 4, there were no statistically significant differences in the Kaplan-Meier curves of
312	fasciculations in the observed survival dataset (observed survival data was recorded for 21 patients, with 28
313	surviving patients censored from the analysis). Similarly, while not significant, there were clear divergences in
314	dichotomized values for FP frequency and FP median amplitude, thus they were implemented in a Cox model.
315	FP frequency and FP median amplitude were associated with hazard ratios of $1.00 (0.99-1.01, p = 0.96)$ and
316	1.00 (0.98-1.03, p = 0.97), respectively.
317	
318	4. Discussion
319	
320	Fasciculations are a hallmark clinical feature of ALS and are reflective of early neuronal dysfunction. Therefore,
321	their measurement and interpretation have the potential to elucidate the processes of neurodegeneration in the
322	early stages of the disease course (Bashford et al., 2019) and expedite diagnosis and prognosis. Despite the
323	evident potential of HDSEMG as a diagnostic or prognostic tool in ALS, it is currently not validated for use in
324	the clinic and remains confined to the research setting. ALS diagnosis and prognosis require an integrative
325	approach, making use of clinical history, physical examination and electrodiagnostic tests (Goutman et al.,
326	2022). Since fasciculation assessment in MG performed poorly as a diagnostic and prognostic tool in isolation,

- 327 we could not justify planned combinatorial analysis with the BB data. However, this study reinforces a
- 328 statistical framework for the future inclusion of multiple muscles as part of a clinically relevant body-map

assessment. Future work is planned from our group, which will focus on the assessment of muscles known to
become weak early in the disease course, such as first dorsal interosseous, abductor pollicis brevis, and tibialis
anterior.

332

333 4.1 Poor diagnostic utility of gastrocnemius HDSEMG data

334

335 Our results show that HDSEMG recording in the MG fails to add any additional diagnostic insight above that 336 already provided by recordings in the BB (Tamborska et al., 2020). This finding is corroborated by previous 337 comparisons of gastrocnemius FP parameters between ALS and neurological controls, showing similar spatial 338 distribution, intensity (the number of FP pairs), amplitude, duration, and number of phases (FP repeats within 339 10-110 ms) between groups (Van Der Heijden et al., 1994, Kleine et al., 2012, Sleutjes et al., 2016). Fermont 340 showed that fasciculations occur frequently in the lower leg muscles of healthy people and may be temporarily 341 increased by physical exercise (Fermont et al., 2010), with the theory being that exercise may induce this 342 increase via metabolic stress. The gastrocnemius has also shown more diurnal variation in FP frequency than the 343 BB (Bashford et al., 2020a), suggesting values recorded in the gastrocnemius may be more sensitive to the exact 344 timing of HDSEMG recording than in BB. Furthermore, fasciculations in ALS patients have been shown to 345 occur more often in proximal than in distal muscles, and markedly more frequently in the upper than in the 346 lower limbs (Krarup, 2011), further promoting the use of BB or other upper limb muscles in the future 347 assessment of the utility of HDSEMG in ALS.

348

349 The limited diagnostic utility of the MG HDSEMG recordings may also be explained by the differences in 350 disease stage between the participants recruited into this study. It has previously been proposed that FP 351 frequency may increase in the early stages of ALS until muscle weakness occurs, after which it subsequently 352 declines (Tamborska et al., 2020). This initial increase may be attributed to the progression of axonal membrane 353 abnormality in the affected neurons (Mills, 2010), whereas the subsequent fall may be attributed to shrinkage of 354 the MU pool and saturation (or reversal) of the relative hyperexcitability of the surviving MUs (Bashford et al., 355 2020c). Considering this, the time point at which each patient undergoes HDSEMG recording may bear an 356 influence on their FP parameter values, as they may be at different stages of their disease course and exhibiting 357 varying stages of neuropathophysiology. Furthermore, the fascicle architecture of the two muscles may have an 358 impact on their relative sampling of MUs. In comparison to the parallel architecture of the BB, the fascicles of 359 the gastrocnemius have a pennate architecture with spatially localised MU territories (Vieira et al., 2011). So, 360 the extent to which the position of the electrode grid influences which MUs are within the detection volume may 361 be greater in the gastrocnemius than in the BB (where the majority of MUs would run beneath the grid). 362 Furthermore, variability in the data analyses between studies e.g., differences in methods of determining FP 363 discharge frequency (De Carvalho and Swash, 2016, Noto et al., 2018), may have a significant influence on 364 studies' results and their subsequent interpretation. 365 366 367

369 4.2 Poor prognostic utility of gastrocnemius HDSEMG data

370

371 Similarly, our study has shown that muscle FP parameters obtained from the MG muscle are not useful at

- 372 prognosticating patients with ALS. This result was mirrored using both predicted survival values from the
- 373 ENCALS Survival Model and real-world observed values.
- 374

375 While our findings are in contradiction with a previous study which focused on BB (Wannop et al., 2021), there 376 are several plausible explanations. This is the first study aimed solely at the prognostic utility of the MG muscle. 377 When examined histologically, the gastrocnemius muscle is comprised mainly of fast-twitch muscle fibres in 378 comparison to the roughly equal ratio of fast twitch to slow twitch found in the BB muscle (Silva Cornachione 379 et al., 2011, Srinivasan et al., 2007). This nuance is important as ALS is known to preferentially affect fast-380 twitch muscle fibres (Atkin et al., 2005). Therefore, as muscle FP parameters are known to fall with disease 381 progression (Bashford et al., 2020c), one may speculate that the disease may progress rapidly in the 382 gastrocnemius and may only prove to be a useful measurement much earlier in the disease course. When 383 examining our patient population, HDSEMG recordings were not performed at the time of symptom onset, with 384 the interquartile range 19-34 months after symptom onset. Therefore, it is possible to speculate that the clinical 385 utility of the MG muscle may have been lost long before recordings were taken, and future studies should aim to

- 386 obtain recordings as soon as a clinical suspicion of ALS arises.
- 387

388 Additionally, we chose a different approach for expressing our fasciculation measures than those employed by 389 Wannop et al. (Wannop et al., 2021). Where our study used single-timepoint, 'raw' recordings, Wannop et al. 390 (Wannop et al., 2021) divided these values by months since symptom onset. We decided against implementing 391 this approach in our study. Firstly, as the ENCALS Survival Model uses time variables to produce a predicted 392 survival time, we wanted to avoid spurious correlations, whereby longer prognoses were incorrectly associated 393 with FP parameters (Bashford et al., 2020c). Secondly, there is a weaker relationship between disease 394 progression and change in fasciculation parameters in the MG muscle in comparison to the BB muscle. In 395 particular, weak gastrocnemius muscles show little to no loss of FP frequency as the disease progresses 396 (Bashford et al., 2020c).

397

398 Through investigating the prognostic utility of the MG muscle, we have shown that HDSEMG recordings have 399 little prognostic utility in the middle-to-late disease course. We have speculated that HDSEMG recordings close 400 to the time of symptom onset may prove to be the most reliable and we hope that the findings from this study 401 can support prospective data collection in other, more reliable muscles.

402

403 4.3 Future directions of study

404

405 This study has shown that the analysis of fasciculations recorded in the MG following symptom onset does not 406 show diagnostic or prognostic utility in ALS. However, HDSEMG may provide a wide range of benefits for 407 ALS patients and their families, as the non-invasive nature of the recording allows for longer recording periods 408 and greater patient comfort (Mateen et al., 2008, Howard and Murray, 1992, Bashford et al., 2019). It is also

409 capable of achieving greater spatial resolution and muscle area coverage than is possible with needle EMG, 410 allowing for more precise anatomical mapping of fasciculations (Drost et al., 2007). Due to this greater 411 coverage, there is also less reliance on the reproduction of needle position in serial recordings, making 412 HDSEMG more suitable for the collection of longitudinal data (Benatar et al., 2016, Bashford et al., 2020b). 413 This is essential for capturing the dynamic changes that occur in ALS due to the inexorable decline of motor 414 neurons (Bashford et al., 2020b). Perhaps the most important benefit of this technique is its ease of application 415 and potential for use outside of the neurophysiology lab. Its use by non-clinicians in the community could 416 provide greater relief to patients and their families as well as benefiting medical research by analysing the 417 disease at a pre-symptomatic stage (Bashford et al., 2020b). 418 419 Therefore, further research into the application of HDSEMG in the diagnosis and prognosis of neuromuscular 420 disease is required and should focus on the BB or other upper limb muscles at an earlier stage in the disease 421 course. Due to the presence of fasciculations in both ALS patients and controls, HDSEMG data should be 422 considered in the context of other clinical factors, such as the distribution of fasciculations, other neurological

423 symptoms, and a clinical suspicion of ALS (Noto et al., 2018, Mills, 2010, Drost et al., 2007, de Carvalho et al.,

424 2017, De Carvalho et al., 2008). A combinatorial approach may be most appropriate for this, using tools such as

425 electrical impedance myography, ultrasound, and magnetic resonance imaging to monitor clinical,

426 electrophysiological, biochemical, and imaging biomarkers simultaneously.

427

Large numbers of patients across the spectrum of ALS phenotypes should also be monitored in longitudinal
studies with post-mortem validation, including prospective multi-centre cohort analyses, to develop reliable and

430 sensitive biomarkers. The greatest diagnostic challenge appears to be in differentiating between ALS and

431 neurological controls. So, a greater range of ALS mimics e.g., spinal muscular atrophy, MMN and spinobulbar

432 muscular atrophy (Kennedy's disease) should be included in neurological control groups.

433

434 <u>5. Conclusion</u>

435

The present study has been successful in producing an analytical framework that may be reproduced for the diagnostic and prognostic evaluation of HDSEMG in novel muscle groups. While our results in MG were negative, we believe this study supports the argument for early HDSEMG recordings across a broader range of clinically relevant muscles in patients with ALS, as it is in these early stages of the disease that fasciculations may prove to be the most valuable.

441

442 <u>6. Funding</u>

443

JB acknowledges funding from the Medical Research Council and Motor Neurone Disease Association (Lady

445 Edith Wolfson Clinical Research Training Fellowship; MR/P000983/1), Sattaripour Charitable Foundation, UK

446 Dementia Research Institute, and the National Institute for Health and Care Research (Academic Clinical

447 Lectureship program). DP, UM, and CC contributed during their MSc qualifications in Clinical Neuroscience.

448 R.I.'s input represents independent research supported by the NIHR BioResource Centre Maudsley at South

449 London and Maudsley NHS Foundation Trust (SLaM) & Institute of Psychiatry, Psychology and Neuroscience 450 (IoPPN), King's College London. RM acknowledges funding from the Faculty of Life Sciences and Medicine, 451 King's College London. 452 453 7. Competing interests 454 455 The authors declare no relevant competing interests. 456 457 8. Figure legends 458 459 Fig. 1: Comparison of fasciculation potential parameters from medial gastrocnemius between the groups. All values were 460 transformed to log(10). Welch's ANOVA with Games-Howell post-hoc test revealed no statistically significant difference 461 between the means of the groups for each of the fasciculation potential parameters. Abbreviations: FP, fasciculation 462 potential; ALS, amyotrophic lateral sclerosis. 463 464 Fig. 2: Assessment of the diagnostic utility of fasciculation potential parameters recorded in the medial gastrocnemius in 465 ALS. ROC analysis, after dichotomising outcomes by combining the neurological and healthy control groups (1 = ALS, 0 =466 not ALS), demonstrated areas under the curve of 0.61, 0.58, and 0.63 for fasciculation frequency, fasciculation amplitude, 467 and fasciculation amplitude dispersion, respectively, each value indicative of a poor diagnostic instrument. 468 469 Fig. 3: A Kaplan-Meier analysis using real-world, observed survival times from a retrospective cohort of patients with ALS. 470 It involved the analysis of three FP parameters: frequency, median amplitude, and amplitude dispersion. Dichotomization 471 into high and low groups occurred at the median value. 472 473 Fig. 4: A Kaplan-Meier analysis using a prospective, predicted patient survival using the ENCALS Survival Model. It 474 involved the analysis of three FP parameters: frequency, median amplitude, and amplitude dispersion. Dichotomization into 475 high and low groups occurred at the median value. 476 477 9. References 478 479 ATKIN, J. D., SCOTT, R. L., WEST, J. M., LOPES, E., QUAH, A. K. J. & CHEEMA, S. S. 2005. Properties of 480 slow- and fast-twitch muscle fibres in a mouse model of amyotrophic lateral sclerosis. Neuromuscular 481 Disorders, 15, 377-388. 482 AVIDAN, R., FAINMESSER, Y., DRORY, V. E., BRIL, V. & ABRAHAM, A. 2021. Fasciculation frequency 483 at the biceps brachii and brachialis muscles is associated with amyotrophic lateral sclerosis disease 484 burden and activity. Muscle & Nerve, 63, 204-208. 485 BASHFORD, J., MASOOD, U., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K. 486 & SHAW, C. 2020a. Fasciculations demonstrate daytime consistency in amyotrophic lateral sclerosis. 487 Muscle & Nerve, 61, 745-750.

488	BASHFORD, J., MILLS, K. & SHAW, C. 2020b. The evolving role of surface electromyography in
489	amyotrophic lateral sclerosis: A systematic review. Clin Neurophysiol, 131, 942-950.
490	BASHFORD, J., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K. & SHAW, C.
491	2019. SPiQE: An automated analytical tool for detecting and characterising fasciculations in
492	amyotrophic lateral sclerosis. Clinical Neurophysiology, 130, 1083-1090.
493	BASHFORD, J. A., WICKHAM, A., INIESTA, R., DRAKAKIS, E. M., BOUTELLE, M. G., MILLS, K. R. &
494	SHAW, C. E. 2020c. The rise and fall of fasciculations in amyotrophic lateral sclerosis. Brain
495	Communications, 2.
496	BENATAR, M., BOYLAN, K., JEROMIN, A., RUTKOVE, S. B., BERRY, J., ATASSI, N. & BRUIJN, L.
497	2016. ALS biomarkers for therapy development: State of the field and future directions. Muscle &
498	Nerve, 53, 169-182.
499	BENATAR, M., TURNER, M. R. & WUU, J. 2019. Defining pre-symptomatic amyotrophic lateral sclerosis.
500	Amyotroph Lateral Scler Frontotemporal Degener, 20, 303-309.
501	BROWN, R. H. & AL-CHALABI, A. 2017. Amyotrophic Lateral Sclerosis. New England Journal of Medicine,
502	377, 162-172.
503	DE CARVALHO, M., DENGLER, R., EISEN, A., ENGLAND, J. D., KAJI, R., KIMURA, J., MILLS, K.,
504	MITSUMOTO, H., NODERA, H., SHEFNER, J. & SWASH, M. 2008. Electrodiagnostic criteria for
505	diagnosis of ALS. Clinical Neurophysiology, 119, 497-503.
506	DE CARVALHO, M., KIERNAN, M. C. & SWASH, M. 2017. Fasciculation in amyotrophic lateral sclerosis:
507	origin and pathophysiological relevance. J Neurol Neurosurg Psychiatry, 88, 773-779.
508	DE CARVALHO, M. & SWASH, M. 2013. Fasciculation potentials and earliest changes in motor unit
509	physiology in ALS. J Neurol Neurosurg Psychiatry, 84, 963-8.
510	DE CARVALHO, M. & SWASH, M. 2016. Fasciculation discharge frequency in amyotrophic lateral sclerosis
511	and related disorders. Clinical Neurophysiology, 127, 2257-2262.
512	DROST, G., KLEINE, B. U., STEGEMAN, D. F., VAN ENGELEN, B. G. & ZWARTS, M. J. 2007.
513	Fasciculation potentials in high-density surface EMG. J Clin Neurophysiol, 24, 301-7.
514	FERMONT, J., ARTS, I. M., OVEREEM, S., KLEINE, B. U., SCHELHAAS, H. J. & ZWARTS, M. J. 2010.
515	Prevalence and distribution of fasciculations in healthy adults: Effect of age, caffeine consumption and
516	exercise. Amyotroph Lateral Scler, 11, 181-6.
517	GORDON, P. H. 2013. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology,
518	Management and Therapeutic Trials. Aging Dis, 4, 295-310.
519	GOUTMAN, S. A., HARDIMAN, O., AL-CHALABI, A., CHIÓ, A., SAVELIEFF, M. G., KIERNAN, M. C. &
520	FELDMAN, E. L. 2022. Recent advances in the diagnosis and prognosis of amyotrophic lateral
521	sclerosis. Lancet Neurol, 21, 480-493.
522	HANNAFORD, A., PAVEY, N., VAN DEN BOS, M., GEEVASINGA, N., MENON, P., SHEFNER, J. M.,
523	KIERNAN, M. C. & VUCIC, S. 2021. Diagnostic Utility of Gold Coast Criteria in Amyotrophic
524	Lateral Sclerosis. Ann Neurol, 89, 979-986.
525	HOWARD, R. S. & MURRAY, N. M. 1992. Surface EMG in the recording of fasciculations. <i>Muscle Nerve</i> , 15,
526	1240-5.

527	KLEINE, B. U., BOEKESTEIN, W. A., ARTS, I. M. P., ZWARTS, M. J., JURGEN SCHELHAAS, H. &
528	STEGEMAN, D. F. 2012. Fasciculations and their F-response revisited: High-density surface EMG in
529	ALS and benign fasciculations. Clinical Neurophysiology, 123, 399-405.
530	KRARUP, C. 2011. Lower motor neuron involvement examined by quantitative electromyography in
531	amyotrophic lateral sclerosis. Clinical Neurophysiology, 122, 414-422.
532	LIU, J., LI, Y., NIU, J., ZHANG, L., FAN, J., GUAN, Y., CUI, L. & LIU, M. 2021. Fasciculation differences
533	between ALS and non-ALS patients: an ultrasound study. BMC Neurology, 21.
534	MATEEN, F. J., SORENSON, E. J. & DAUBE, J. R. 2008. Strength, physical activity, and fasciculations in
535	patients with ALS. Amyotrophic Lateral Sclerosis, 9, 120-121.
536	MILLS, K. R. 2010. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign
537	fasciculation syndrome. Brain, 133, 3458-3469.
538	NOTO, YI., SIMON, N. G., SELBY, A., GARG, N., SHIBUYA, K., SHAHRIZAILA, N., HUYNH, W.,
539	MATAMALA, J. M., DHARMADASA, T., PARK, S. B., VUCIC, S. & KIERNAN, M. C. 2018.
540	Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral
541	sclerosis. Clinical Neurophysiology, 129, 974-980.
542	OPIE-MARTIN, S., OSSHER, L., BREDIN, A., KULKA, A., PEARCE, N., TALBOT, K. & AL-CHALABI,
543	A. 2021. Motor Neuron Disease Register for England, Wales and Northern Ireland-an analysis of
544	incidence in England. Amyotroph Lateral Scler Frontotemporal Degener, 22, 86-93.
545	PAGANONI, S., MACKLIN, E. A., LEE, A., MURPHY, A., CHANG, J., ZIPF, A., CUDKOWICZ, M. &
546	ATASSI, N. 2014. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).
547	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15, 453-456.
548	SILVA CORNACHIONE, A., CAÇÃO OLIVEIRA BENEDINI-ELIAS, P., CRISTINA POLIZELLO, J.,
549	CÉSAR CARVALHO, L. & CLÁUDIA MATTIELLO-SVERZUT, A. 2011. Characterization of Fiber
550	Types in Different Muscles of the Hindlimb in Female Weanling and Adult Wistar Rats. ACTA
551	HISTOCHEMICA ET CYTOCHEMICA, 44, 43-50.
552	SLEUTJES, B. T. H. M., GLIGORIJEVIĆ, I., MONTFOORT, I., VAN DOORN, P. A., VISSER, G. H. &
553	BLOK, J. H. 2016. Identifying fasciculation potentials in motor neuron disease: A matter of
554	probability. Muscle & Nerve, 53, 227-233.
555	SRINIVASAN, R. C., LUNGREN, M. P., LANGENDERFER, J. E. & HUGHES, R. E. 2007. Fiber type
556	composition and maximum shortening velocity of muscles crossing the human shoulder. Clinical
557	Anatomy, 20, 144-149.
558	TAMBORSKA, A., BASHFORD, J., WICKHAM, A., INIESTA, R., MASOOD, U., CABASSI, C., PLANINC,
559	D., HODSON-TOLE, E., DRAKAKIS, E., BOUTELLE, M., MILLS, K. & SHAW, C. 2020. Non-
560	invasive measurement of fasciculation frequency demonstrates diagnostic accuracy in amyotrophic
561	lateral sclerosis. Brain Communications, 2.
562	TSUGAWA, J., DHARMADASA, T., MA, Y., HUYNH, W., VUCIC, S. & KIERNAN, M. C. 2018.
563	Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical
564	Neurophysiology, 129, 2149-2154.

565	VAN DER HEIJDEN, A., SPAANS, F. & REULEN, J. 1994. Fasciculation potentials in foot and leg muscles of
566	healthy young adults. Electroencephalography and Clinical Neurophysiology/Evoked Potentials
567	Section, 93, 163-168.
568	VAN ES, M. A., HARDIMAN, O., CHIO, A., AL-CHALABI, A., PASTERKAMP, R. J., VELDINK, J. H. &
569	VAN DEN BERG, L. H. 2017. Amyotrophic lateral sclerosis. The Lancet, 390, 2084-2098.
570	VIEIRA, T. M. M., LORAM, I. D., MUCELI, S., MERLETTI, R. & FARINA, D. 2011. Postural activation of
571	the human medial gastrocnemius muscle: are the muscle units spatially localised? The Journal of
572	Physiology, 589, 431-443.
573	WANNOP, K., BASHFORD, J., WICKHAM, A., INIESTA, R., DRAKAKIS, E., BOUTELLE, M., MILLS, K.
574	& SHAW, C. 2021. Fasciculation analysis reveals a novel parameter that correlates with predicted
575	survival in amyotrophic lateral sclerosis. Muscle & Nerve, 63, 392-396.
576	WESTENENG, HJ., DEBRAY, T. P. A., VISSER, A. E., VAN EIJK, R. P. A., ROONEY, J. P. K., CALVO,
577	A., MARTIN, S., MCDERMOTT, C. J., THOMPSON, A. G., PINTO, S., KOBELEVA, X.,
578	ROSENBOHM, A., STUBENDORFF, B., SOMMER, H., MIDDELKOOP, B. M., DEKKER, A. M.,
579	VAN VUGT, J. J. F. A., VAN RHEENEN, W., VAJDA, A., HEVERIN, M., KAZOKA, M.,
580	HOLLINGER, H., GROMICHO, M., KÖRNER, S., RINGER, T. M., RÖDIGER, A., GUNKEL, A.,
581	SHAW, C. E., BREDENOORD, A. L., VAN ES, M. A., CORCIA, P., COURATIER, P., WEBER, M.,
582	GROSSKREUTZ, J., LUDOLPH, A. C., PETRI, S., DE CARVALHO, M., VAN DAMME, P.,
583	TALBOT, K., TURNER, M. R., SHAW, P. J., AL-CHALABI, A., CHIÒ, A., HARDIMAN, O.,
584	MOONS, K. G. M., VELDINK, J. H. & VAN DEN BERG, L. H. 2018. Prognosis for patients with
585	amyotrophic lateral sclerosis: development and validation of a personalised prediction model. The
586	Lancet Neurology, 17, 423-433.



ALS Neuro Control Control



Fasc. FrequencyMedian Amp.Amp. Dispersion

Sensitivity



